Devilli Lara, Garonzi Chiara, Balter Rita, Bonetti Elisa, Chinello Matteo, Zaccaron Ada, Vitale Virginia, De Bortoli Massimilano, Caddeo Giulia, Baretta Valentina, Tridello Gloria, Cesaro Simone
Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Hematol Rep. 2021 Mar 5;13(1):8847. doi: 10.4081/hr.2021.8847.
Long-term survival for acute lymphoblastic leukemia (ALL) in children improved over the last three decades up to 80-90% of affected patients. Consequently, the quality of life of survivors has become increasingly important. This study analyses the clinical features and outcome of 119 children with ALL, focusing on the quality of long-term survival in a subset of 22 patients over 18 years of age. Among this group, the 10-year event-free survival and overall survival were 83.1% (C.I. 74.0-89.2) and 88.4% (C.I. 80.9-93.1), respectively. Treatment related long-term medical complications were reported only in 2 patients (9.1%). Secondary school was completed successfully in 20 of 22 patients (89.9%). The remaining 2 patients were still attending at the time of the analysis. In conclusion, current treatment for ALL is well tolerated and does not compromise significantly the quality of life of survivors.
在过去三十年中,儿童急性淋巴细胞白血病(ALL)患者的长期生存率提高到了80%-90%。因此,幸存者的生活质量变得越来越重要。本研究分析了119例ALL患儿的临床特征和预后,重点关注了22例18岁以上患儿的长期生存质量。在该组中,10年无事件生存率和总生存率分别为83.1%(置信区间74.0-89.2)和88.4%(置信区间80.9-93.1)。仅2例患者(9.1%)报告了与治疗相关的长期医疗并发症。22例患者中有20例(89.9%)成功完成了中学学业。在分析时,其余2例患者仍在上学。总之,目前ALL的治疗耐受性良好,不会显著影响幸存者的生活质量。